7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Inclusion Criteria

• •Part I (closed to accrual as of 6/8/2007)
• •* Histologically confirmed solid tumor that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective, including the following:
• •* Gastrointestinal tract cancer
• •* Lung cancer
• •* Breast cancer
• •* Ovarian cancer
• •* Endometrial cancer
• •* Cervical cancer
• •* Prostate cancer
• •* Head and neck cancer
• •* Patients with or without measurable or evaluable disease allowed
• •* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion \> 20 mm by conventional techniques or ≥ 10 mm with spiral CT scan
• •* Tumor markers allowed for evaluable disease
• •* Positive bone scan, osteoblastic metastases, and pleural or peritoneal effusions are not considered measurable or evaluable disease
• •* No known brain metastases
• •Part II
• •* Histologically confirmed (either primary or the recurrent site) locally recurrent or metastatic breast cancer not amendable to surgery
• •* Measurable disease
• •* For skin lesions, documentation by color photography and estimation of lesion size with a ruler are required
• •* Must have undergone prior therapy with an anthracycline and a taxane either in the adjuvant or metastatic setting
• •* CNS metastasis allowed provided stable disease (i.e., no evidence of local progression) ≥ 3 months after local therapy
• •* Hormone receptor status:
• •* Estrogen receptor negative
• •* Progesterone receptor negative
• •* HER-2 not amplified by fluorescence in situ hybridization
• •Performance status - ECOG 0-2
• •Performance status - Karnofsky 60-100%
• •More than 12 weeks
• •WBC at least 3,000/mm\^3
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hemoglobin ≥ 10 g/dL
• •Bilirubin normal
• •AST/ALT no greater than 3 times upper limit of normal (ULN)
• •No Gilbert's disease
• •No chronic unconjugated hyperbilirubinemia
• •Creatinine no greater than 1.5 times ULN
• •Creatinine clearance at least 60 mL/min
• •No symptomatic cardiac dysfunction
• •No symptomatic pulmonary dysfunction
• •Oxygen saturation at least 90% by pulse oximetry on room air at rest and after walking 6 minutes
• •No insulin-dependent diabetes mellitus
• •No other uncontrolled concurrent illness
• •No active or ongoing infection
• •No psychiatric illness or social situation that would preclude study entry
• •No prior allergic reactions attributed to compounds of similar chemical or biological composition to UCN-01 or irinotecan
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No concurrent granulocyte colony-stimulating factors (filgrastim \[G-CSF\] or sargramostim \[GM-CSF\]) during the first course of study
• •See Disease Characteristics (Part II)
• •More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• •Prior irinotecan allowed
• •Less than 4 prior chemotherapy regimens in the adjuvant and/or metastatic setting (Part II)
• •More than 4 weeks since prior radiotherapy and recovered
• •Concurrent warfarin allowed
• •Concurrent subcutaneous heparin allowed
• •No other concurrent investigational agents
• •No concurrent anticonvulsants (e.g., carbamazepine, phenobarbital, or phenytoin)
• •No concurrent combination antiretroviral therapy for HIV-positive patients